Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael B Atkins

Showing results (61-70 of 338) with videos related to

Pageof 34
Sort By:
The New England Journal of Medicine|February 8, 2008
Melanoma complicating treatment with natalizumab for multiple sclerosisJohn T Mullen, Timothy K Vartanian, Michael B Atkins
Melanoma Research|July 9, 2014
Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case reportSuthee Rapisuwon, Kellie Parks, Waddah Al-Refaie, et al.
Journal for Immunotherapy of Cancer|August 7, 2019
A case of checkpoint inhibitor-induced celiac diseaseDana Alsaadi, Neil J Shah, Aline Charabaty, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 21, 2017
Indoor Tanning Dependence in Young Adult WomenDarren Mays, Michael B Atkins, Jaeil Ahn, et al.
Cancer Research|February 3, 2006
The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cellsDavid J Panka, Wei Wang, Michael B Atkins, et al.
Cancer Research|October 17, 2019
Retraction: The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma CellsDavid J Panka, Wei Wang, Michael B Atkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancerDaniel Cho, Sabina Signoretti, Meredith Regan, et al.
ACG Case Reports Journal|March 9, 2018
Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor-Induced EnteritisPietro Diana, Charoen Mankongpaisarnrung, Michael B Atkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2015
Toxicities of Immunotherapy for the PractitionerJeffrey S Weber, James C Yang, Michael B Atkins, et al.
JCO Clinical Cancer Informatics|May 14, 2021
Automated Identification of Patients With Immune-Related Adverse Events From Clinical Notes Using Word Embedding and Machine LearningSamir Gupta, Anas Belouali, Neil J Shah, et al.
Pageof 34

Showing results (61-70 of 338) with videos related to

Sort By:
Pageof 34
The New England Journal of Medicine|February 8, 2008
Melanoma complicating treatment with natalizumab for multiple sclerosisJohn T Mullen, Timothy K Vartanian, Michael B Atkins
Melanoma Research|July 9, 2014
Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case reportSuthee Rapisuwon, Kellie Parks, Waddah Al-Refaie, et al.
Journal for Immunotherapy of Cancer|August 7, 2019
A case of checkpoint inhibitor-induced celiac diseaseDana Alsaadi, Neil J Shah, Aline Charabaty, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 21, 2017
Indoor Tanning Dependence in Young Adult WomenDarren Mays, Michael B Atkins, Jaeil Ahn, et al.
Cancer Research|February 3, 2006
The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cellsDavid J Panka, Wei Wang, Michael B Atkins, et al.
Cancer Research|October 17, 2019
Retraction: The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma CellsDavid J Panka, Wei Wang, Michael B Atkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancerDaniel Cho, Sabina Signoretti, Meredith Regan, et al.
ACG Case Reports Journal|March 9, 2018
Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor-Induced EnteritisPietro Diana, Charoen Mankongpaisarnrung, Michael B Atkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2015
Toxicities of Immunotherapy for the PractitionerJeffrey S Weber, James C Yang, Michael B Atkins, et al.
JCO Clinical Cancer Informatics|May 14, 2021
Automated Identification of Patients With Immune-Related Adverse Events From Clinical Notes Using Word Embedding and Machine LearningSamir Gupta, Anas Belouali, Neil J Shah, et al.
Pageof 34